邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

妊娠期系统性红斑狼疮综合管理

崔阳,  张晓

downloadPDF
文章导航 > 协和医学杂志  > 2020 >  11(3): 270-275
崔阳, 张晓. 妊娠期系统性红斑狼疮综合管理[J]. 协和医学杂志, 2020, 11(3): 270-275. doi: 10.3969/j.issn.1674-9081.20200026
引用本文: 崔阳, 张晓. 妊娠期系统性红斑狼疮综合管理[J]. 协和医学杂志, 2020, 11(3): 270-275. doi: 10.3969/j.issn.1674-9081.20200026
shu
Yang CUI, Xiao ZHANG. Comprehensive Management of Systemic Lupus Erythematosus During Pregnancy[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 270-275. doi: 10.3969/j.issn.1674-9081.20200026
Citation: Yang CUI, Xiao ZHANG. Comprehensive Management of Systemic Lupus Erythematosus During Pregnancy[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 270-275. doi: 10.3969/j.issn.1674-9081.20200026
shu

妊娠期系统性红斑狼疮综合管理

doi: 10.3969/j.issn.1674-9081.20200026

  • 广东省人民医院(广东省医学科学院)风湿免疫科, 广州 510000

详细信息
    通讯作者:

    张晓  电话:020-83824249,E-mail:13922255387@163.com

  • 中图分类号: R593.24;R715

Comprehensive Management of Systemic Lupus Erythematosus During Pregnancy

  • Department of Rheumatology and Immunology, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou 510000, China

More Information

    摘要
  • 摘要: 系统性红斑狼疮(systemic lupus erythematosus, SLE)是一种育龄期,尤其是20~40岁女性高发的疾病。此年龄段患者多有怀孕生子的需求,但SLE患者合并妊娠时不但疾病本身可能反复或加重,不良妊娠风险亦显著增加,因此做好SLE患者妊娠期综合管理极其重要。本文主要阐述SLE与妊娠的相互影响及妊娠期SLE患者的综合管理,以期指导临床更好地认识该问题,从而改善SLE患者的妊娠结局。
    Abstract: Systemic lupus erythematosus(SLE) is a disease with a high incidence in women of childbearing age, especially 20-40 years old. Most patients at this age will have the need for pregnancy. However, when SLE combines with pregnancy, pregnant women are facing not only the risk of relapse and aggravation of lupus, but also the increased risk of adverse pregnancies. Therefore, it is very important to do well in the comprehensive management of pregnancy in SLE patients. This paper focused on the interaction between SLE and pregnancy, as well as the management of SLE in pregnant patients, aiming to better understand and improve the pregnancy outcome of SLE patients.
    利益冲突  无
    • HTML全文
    • 参考文献(40)
  • [1] Park MC, Park YB, Jung SY, et al. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy[J]. Lupus, 2004,13:569-574. doi:  10.1191/0961203304lu1063oa
    [2] Jakobsen IM, Helmig RB, Stengaard-Pedersen K. Maternal and foetal outcomes in pregnant systemic lupus erythematosus patients:an incident cohort from a stable referral population followed during 1990-2010[J]. Scand J Rheumatol, 2015,44:377-384. doi:  10.3109/03009742.2015.1013982
    [3] Palma Dos Reis CR, Cardoso G, Carvalho C, et al. Prediction of Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus[J]. Clin Rev Allergy Immunol, 2019.doi:10.1007/s12016-019-08762-9.[Epub ahead of print].
    [4] Sammaritano LR. Management of Systemic Lupus Erythematosus During Pregnancy[J]. Annu Rev Med, 2017,68:271-285. doi:  10.1146/annurev-med-042915-102658
    [5] Tedeschi SK, Massarotti E, Guan H, et al. Specific systemic lupus erythematosus disease manifestations in the six months prior to conception are associated with similar disease manifestations during pregnancy[J]. Lupus, 2015,24:1283-1292. doi:  10.1177/0961203315586455
    [6] Kattah AG, Garovic VD. Pregnancy and Lupus Nephritis[J]. Semin Nephrol, 2015,35:487-499. doi:  10.1016/j.semnephrol.2015.08.010
    [7] Cozzani E, Drosera M, Gasparini G, et al. Serology of Lupus Erythematosus:Correlation between Immunopathologi-cal Features and Clinical Aspects[J]. Autoimmune Dis, 2014,2014:321359. https://www.hindawi.com/journals/ad/2014/321359/
    [8] Teng YKO, Bredewold EOW, Rabelink TJ, et al. An evidence-based approach to pre-pregnancy counselling for pa-tients with systemic lupus erythematosus[J].Rheumatology, 2018,57:1707-1720. doi:  10.1093/rheumatology/kex374
    [9] Brito-Zerón P, Izmirly PM, Ramos-Casals M, et al. The clinical spectrum of autoimmune congenital heart block[J]. Nat Rev Rheumatol, 2015,11:301-312. doi:  10.1038/nrrheum.2015.29
    [10] Kan N, Silverman ED, Kingdom J, et al. Serial echocardiography for immune-mediated heart disease in the fetus:results of a risk-based prospective surveillance strategy[J]. Prenat Diagn, 2017,37:375-382. doi:  10.1002/pd.5021
    [11] Maynard S, Guerrier G, Duffy M. Pregnancy in Women With Systemic Lupus and Lupus Nephritis[J]. Adv Chronic Kidney Dis, 2019,26:330-337. doi:  10.1053/j.ackd.2019.08.013
    [12] Nahal SK, Selmi C, Gershwin ME. Safety issues and recommendations for successful pregnancy outcome in systemic lupus erythematosus[J]. J Autoimmun, 2018,93:16-23. doi:  10.1016/j.jaut.2018.07.016
    [13] Lazzaroni MG, Dall Ara F, Fredi M, et al. A comprehensive review of the clinical approach to pregnancy and systemic lupus erythematosus[J]. J Autoimmun, 2016,74:106-117. doi:  10.1016/j.jaut.2016.06.016
    [14] Petri M. Pregnancy and Systemic Lupus Erythematosus[J]. Best Pract Res Clin Obstet Gynaecol, 2019,19:30133-30136. https://www.sciencedirect.com/science/article/pii/S1521693419301336
    [15] Espinosa G, Cervera R. Current treatment of antiphos-pholipid syndrome:lights and shadows[J]. Nat Rev Rheumatol, 2015,11:586-596. doi:  10.1038/nrrheum.2015.88
    [16] Hwang J, Shin S, Kim Y, et al. Epidemiology of Antiphospholipid Syndrome in Korea:a Nationwide Population-based Study[J]. J Korean Med Sci, 2020,35:e35. doi:  10.3346/jkms.2020.35.e35
    [17] Limper M, de Leeuw K, Lely AT, et al. Diagnosing and treating antiphospholipid syndrome:a consensus paper[J]. Neth J Med, 2019,77:98-108.
    [18] Lazzaroni MG, Dall Ara F, Fredi M, et al. A comprehensive review of the clinical approach to pregnancy and systemic lupus erythematosus[J]. J Autoimmun, 2016,74:106-117. doi:  10.1016/j.jaut.2016.06.016
    [19] Cavazzana I, Andreoli L, Limper M, et al. Update on Antiphospholipid Syndrome:Ten Topics in 2017[J]. Curr Rheumatol Rep, 2018,20:15. doi:  10.1007/s11926-018-0718-4
    [20] Andreoli L, Fredi M, Nalli C, et al. Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome[J]. J Autoimmun, 2012,38:J197-J208. doi:  10.1016/j.jaut.2011.11.010
    [21] Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome[J]. Lancet, 2010,376:1498-1509. doi:  10.1016/S0140-6736(10)60709-X
    [22] Buyon JP, Kim MY, Guerra MM, et al. Predictors of Pregnancy Outcomes in Patients With Lupus[J]. Ann Intern Med, 2015,163:153. doi:  10.7326/M14-2235
    [23] Liu T, Gu J, Wan L, et al. "Non-criteria" antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort[J].Arthritis Res Ther, 2020,22:33. doi:  10.1186/s13075-020-2131-4
    [24] Marchetti T, Ribi C, Perneger T, et al. Prevalence, persistence and clinical correlations of classic and novel antiphospholipid antibodies in systemic lupus erythematosus[J].Rheumatology, 2018,57:1350-1357. doi:  10.1093/rheumatology/key095
    [25] Bertin D, Beziane A, Resseguier N, et al. Interest of IgG and IgM antiprothrombin autoantibodies in the exploration of antiphospholipid syndrome:a 5-year retrospective study[J]. Rheumatology (Oxford), 2019, pii:z453. doi:  10.1093/rheumatology/kez453/5599884
    [26] Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults[J]. Ann Rheum Dis, 2019,78:1296-1304. doi:  10.1136/annrheumdis-2019-215213
    [27] 中国系统性红斑狼疮研究协作组专家组, 国家风湿病数据中心. 中国系统性红斑狼疮患者围产期管理建议[J]. 中华医学杂志, 2015,95:1056-1060. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyx201514005
    [28] Martínez López JA, García Vivar ML, Cáliz R, et al. Recomendaciones sobre actuaciones a seguir durante la edad fértil, el embarazo, posparto y lactancia en pacientes con enfermedades reumáticas inflamatorias y autoinmunes[J]. Reumatología Clínica, 2017,13:264-281.
    [29] Sammaritano L, Bermas B, Chambers C, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.[J]. Arthritis Care Res, 2020,72:461-488. doi:  10.1002/acr.24130
    [30] Cyprian F, Lefkou E, Varoudi K, et al. Immunomodulatory Effects of Vitamin D in Pregnancy and Beyond[J]. Front Immunol, 2019,10:2739. doi:  10.3389/fimmu.2019.02739
    [31] Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I:standard and biologic disease modifying anti-rheumatic drugs and corticosteroids[J]. Rheumatology(Oxford), 2016,55:1693-1697. doi:  10.1093/rheumatology/kev404
    [32] Marder W. Update on pregnancy complications in systemic lupus erythematosus[J]. Curr Opin Rheumatol, 2019,31:650-658. doi:  10.1097/BOR.0000000000000651
    [33] Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation[J]. Ann Rheum Dis, 2016,75:795-810. doi:  10.1136/annrheumdis-2015-208840
    [34] Liu X, Qiu Y, Yu ED, et al. Comparison of therapeutic interventions for recurrent pregnancy loss in association with antiphospholipid syndrome:A systematic review and network meta-analysis[J]. Am J Reprod Immunol, 2019,83:e13219. doi:  10.1111/aji.13219
    [35] Sciascia S, Hunt BJ, Talavera-Garcia E, et al. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies[J].Am J Obstet Gynecol, 2016,214:271-273. https://www.ncbi.nlm.nih.gov/pubmed/26429521
    [36] Mekinian A, Lazzaroni MG, Kuzenko A, et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome:Data from a European multicenter retrospective study[J]. Autoimmun Rev, 2015,14:498-502. doi:  10.1016/j.autrev.2015.01.012
    [37] Bramham K, Thomas M, Nelson-Piercy C, et al. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss[J]. Blood, 2011,117:6948-6951. doi:  10.1182/blood-2011-02-339234
    [38] Svenungsson E, Antovic A. The Antiphospholipid Syndrome-often overlooked cause of vascular occlusions?[J]. J Intern Med, 2020,287:349-372. doi:  10.1111/joim.13022
    [39] Sammaritano LR, Bermas BL. Management of pregnancy and lactation[J]. Best Pract Res Clin Rheumatol, 2018,32:750-766. doi:  10.1016/j.berh.2019.03.007
    [40] Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation[J]. Ann Rheum Dis, 2016,75:795-810. doi:  10.1136/annrheumdis-2015-208840
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  295
  • HTML全文浏览量:  22
  • PDF下载量:  133
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-02-05
  • 刊出日期:  2020-05-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！